Conv. Plasma
Nigella Sativa

All nitazoxanide studies
Meta analysis
study COVID-19 treatment researchNitazoxanideNitazoxanide (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

Walker et al., Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2463 (date from preprint), NCT04746183
Sep 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Phase I trial of high dose nitazoxanide, 1500mg twice daily, with 14 participants. Treatment was safe and well tolerated. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target concentration after the first dose and maintained throughout. NCT04746183 (history).
Walker et al., 11 Sep 2021, peer-reviewed, 33 authors, trial NCT04746183 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2
Dr Lauren E Walker, Richard Fitzgerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith K R Rajoli, Laura Else, Sujan Dilly‐penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Emmanuel Okenyi, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher
Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2463
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.
Arshad, Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clin Pharmacol Ther
Blum, Nitazoxanide superiority to placebo to treat moderate COVID-19 -A Pilot prove of concept randomized double-blind clinical trial, EClinicalMedicine
Bobrowski, Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Boffito, Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development, Clin Pharmacol Ther
Borchers, pracma: Practical Numerical Math Functions. R package version 2
Braga, Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia, Nature
Cao, Forrest, Zhang, A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs, Antiviral Res
Choi, Arya, Reynolds, Clinical Pharmacology-Informed Development of COVID-19 Therapeutics: Regulatory Experience, Clin Pharmacol Ther
Dang, Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response, Antimicrob Agents Chemother
Dang, Opposing Effects of Nitazoxanide on Murine and Human Norovirus, J Infect Dis
Griffiths, ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial, Trials
Haffizulla, Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial, Lancet Infect Dis
Hiscox, Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?, J Antimicrob Chemother
Hoffmann, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature
Keiser, The drugs we ahve and the drugs we need against major helminth infections
Korba, Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication, Antiviral Res
Korba, Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide, Antimicrob Agents Chemother
Koszalka, Tilmanis, Hurt, Influenza antivirals currently in late-phase clinical trial, Influenza Other Respir Viruses
Maurer, Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics, Clin Pharmacol Ther
Miner, Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways, Front Pharmacol
Portal, Nitazoxanide, None
Rajoli, Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis, Br J Clin Pharmacol
Rajoli, Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis, British Journal of Clinical Pharmacology
Rannard, Mcdonald, Owen, Chasing COVID-19 chemotherapeutics without putting the cart before the horse, Br J Clin Pharmacol
Riccio, Rossi, Piacentini, Rossignol, Santoro, Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by the broad-spectrum anti-infective drug nitazoxanide
Rosenke, Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
Rossignol, El-Gohary, Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial, Aliment Pharmacol Ther
Rossignol, Nitazoxanide: a first-in-class broad-spectrum antiviral agent, Antiviral Res
Rossignol, Oaks, Bostick, Vora, Fulgencio et al., Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Rossignol, Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level, J Biol Chem
Rossignol, Thiazolides: a new class of antiviral drugs, Expert Opin Drug Metab Toxicol
Savic, Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability, Antimicrob Agents Chemother
Stockis, Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d, Int J Clin Pharmacol Ther
Team, R: A language and environment for statistical computing
Thorlund, A real-time dashboard of clinical trials for COVID-19, Lancet Digit Health
Trabattoni, Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication, Sci Rep
Wages, Conaway, O'quigley, Continual reassessment method for partial ordering, Biometrics
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop